Frontlight ResearchEarly access
CompletedNo phase
An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders
Key facts
- Who runs it
- Lupin Ltd.
- Where
- France, Germany, and United Kingdom6 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 53 people enrolled
- Started
- 17 Dec 2020
- Ended
- 16 Jan 2026
- Type of study
- Observational
- Treatments tested
- Mexiletine
- Record updated
- 22 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Adult, male or female patients with non-dystrophic myotonic disorders planned to be started on Namuscla according to the approved SmPC
- Patients already receiving Namuscla/mexiletine for the treatment of NDM; (for patients on mexiletine other than Namuscla, only those who switch to Namuscla will be enrolled)
- Patients who understand and are willing to provide informed consent
Who cannot take part
- Patients who are enrolled or participating in any other clinical trial for an investigational product. -
- Patients receiving drugs that can induce torsades de pointes
- Patients receiving medicinal products with narrow therapeutic index (ie, theophylline, tizanidine, digoxin, lithium, phenytoin or warfarin)
- Hypersensitivity to mexiletine, or to any of the excipients of Namuscla, or hypersensitivity to any local anaesthetic
- Complete heart block (ie, third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 240 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),
- Myocardial infarction (acute or past), or abnormal Q-waves
- Symptomatic coronary artery disease
- Heart failure with reduced ejection fraction <50%
- Ventricular tachyarrhythmia
- Atrial tachyarrhythmia, fibrillation or flutter
- Sinus node dysfunction (including sinus rate < 50 bpm)
- Patients who are pregnant or lactating
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a non-interventional, prospective, observational, multicentre study to evaluate the long-term safety and effectiveness of Namuscla in adult patients with NDM.
Treatments tested
- Mexiletine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Observational Study to Describe the Long-term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients With Non-dystrophic Myotonic Disorders
- Record updated
- 22 June 2026